Published: November 2018 (Web posted: October 2018)
Read Executive Summary Read Full-Text Guideline
This guideline discusses how moderately hypofractionated and ultrahypofractionated schedules compare to conventional regimens in terms of prostate cancer control, toxicity and quality of life and the effect of patient and tumor factors on the appropriateness of hypofractionated radiation therapy. It also addresses appropriate dose-fractionation for both moderate and ultrahypofractionation. Additionally, normal tissue constraints and treatment volumes for hypofractionation and the role of image-guided and intensity-modulated radiation therapy in using these regimens were evaluated.
Developed in collaboration with:
Endorsed by:
Resources: Implementation of Hypofractionated Prostate RT in the U.S.: A NCDB Analysis (CME) Clinical Controversies (CME) Podcast with Guideline Chairs Guideline Slide set Patient Brochure
We have recently updated our privacy policy and terms of use. By using this site, you agree to ASTRO’s Privacy Policy and Terms of Use. We use cookies to provide, secure and improve our services to you. To learn more, click here.